Israel Englander’s Rhythm Pharmaceuticals RYTM Stock Holding History

Israel Englander’s Portfolio RYTM Stock Details RYTM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-25,500	Closed	-$2.58M	–	6393
2025 Q3	$2.58M	Buy	+25,500	New	+$2.37M	﹤0.01%	3814
2024 Q2	–	Sell	-10,000	Closed	-$433K	–	6450
2024 Q1	$433K	Buy	+10,000	New	+$438K	﹤0.01%	4907
2023 Q4	–	Sell	-30,200	Closed	-$692K	–	6473
2023 Q3	$692K	Buy	+30,200	New	+$676K	﹤0.01%	4447
2023 Q2	–	Sell	-80,000	Closed	-$1.43M	–	6613
2023 Q1	$1.43M	Buy	+80,000	New	+$2.01M	﹤0.01%	3754
2021 Q4	–	Sell	-40,000	Closed	-$522K	–	7310
2021 Q3	$522K	Buy	+40,000	New	+$611K	﹤0.01%	5309
2021 Q2	–	Sell	-10,000	Closed	-$213K	–	7032
2021 Q1	$213K	Buy	10,000 +3,000	+43%	+$87K	﹤0.01%	5461
2020 Q4	$208K	Buy	+7,000	New	+$178K	﹤0.01%	4781

Other funds holding RYTM

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Israel Englander's RYTM Position: Q2 2026 in Review

Israel Englander reduced its Rhythm Pharmaceuticals (RYTM) stake by 30% in Q2 2026, selling an estimated $12.2M and leaving 316,719 shares worth $35.2M. The position accounts for 0.01% of the portfolio, ranked #1148.

Israel Englander first reported a position in RYTM in Q2 2018 and has held it in 24 quarters since. The position peaked at $39.3M in Q1 2026. 300 funds tracked by Wall St. Rank hold RYTM as of Q2 2026.

Israel Englander held 316,719 shares of Rhythm Pharmaceuticals worth $35.2M as of Q2 2026.
Israel Englander sold 135,106 Rhythm Pharmaceuticals shares in Q2 2026, an estimated $12.2M.
Rhythm Pharmaceuticals made up 0.01% of Israel Englander's portfolio in Q2 2026, its #1148 holding.
Israel Englander first reported a position in Rhythm Pharmaceuticals in Q2 2018 and has held it in 24 quarters since.
Israel Englander's Rhythm Pharmaceuticals position peaked at $39.3M in Q1 2026.
300 funds tracked by Wall St. Rank held Rhythm Pharmaceuticals as of Q2 2026.

Based on Millennium Management's 13F filing for Q2 2026, filed 14 Aug 2026.